-
Glycaemic patterns during breastfeeding with postpartum use of closed-loop insulin delivery in women with type 1 diabetes Diabetol. (IF 8.4) Pub Date : 2024-07-19 Lois E. Donovan, Rhonda C. Bell, Denice S. Feig, Patricia Lemieux, Helen R. Murphy, Ronald J. Sigal, Josephine Ho, Heidi Virtanen, Susan Crawford, Jennifer M. Yamamoto
-
Sitting Time and Its Interaction With Physical Activity in Relation to All-Cause and Heart Disease Mortality in U.S. Adults With Diabetes Diabetes Care (IF 14.8) Pub Date : 2024-07-19 Wen Dai, Sandra S. Albrecht
OBJECTIVE To evaluate whether associations between sitting time and all-cause and heart disease mortality are modified by physical activity in adults with diabetes. RESEARCH DESIGN AND METHODS Data came from 6,335 U.S. adults with diabetes from National Health and Nutrition Examination Survey 2007–2018 (baseline), with mortality follow-up through 2019. Sitting time and moderate to vigorous physical
-
1113-P: Utilizing a Novel Telemedicine Clinic for Managing Type 2 Diabetes—A Six-Month Pilot Study Diabetes (IF 6.2) Pub Date : 2024-07-19 FIORELLA SOTOMAYOR, CHIKARA GOTHONG, REYNIER HERNANDEZ, MONICA Y. CHOE, GARRETT I. ASH, WILLIAM H. SCOTT, LILLIAN PINAULT, FERNANDO GOMEZ-PERALTA, LAKSHMI G. SINGH, JOHN D. SORKIN, ILIAS (ELIAS) SPANAKIS
Introduction & Objective: RCT aimed to assess if a Diabetes Advanced Telemedicine (DAT) clinic leads to improvement in glycemic control compared to standard of care (SoC). Methods: Patients with type 2 diabetes (T2D) randomized to DAT or SoC. DAT used continuous glucose monitoring devices, smart insulin pens, telecommunication (i.e. video visits) with physical activity (PA) counseling by an exercise
-
344-OR: The MOTS-c/CK2 Pathway Is a Novel Molecular Target for Type 2 Diabetes in East Asians Diabetes (IF 6.2) Pub Date : 2024-07-19 HIROSHI KUMAGAI, SU JEONG KIM, BRENDAN MILLER, SHIN HYUNG LEE, HIROFUMI ZEMPO, TOSHIHARU NATSUME, JUNXIANG WAN, RICARDO RAMIREZ, HEMAL H. MEHTA, YUICHIRO NISHIDA, NORIYUKI FUKU, SHOHEI DOBASHI, ERI MIYAMOTO-MIKAMI, HISASHI NAITO, MEGUMI HARA, CHIHARU IWASAKA, YOSUKE YAMADA, YASUKI HIGAKI, KEITARO TANAKA, KELVIN YEN, PINCHAS COHEN
Introduction & Objective: MOTS-c is a mitochondrial DNA-encoded microprotein that improves impaired glucose metabolism caused by aging and high fat diet. The presence of a naturally occurring genetic variant of MOTS-c, K14Q MOTS-c, increases the susceptibility to type 2 diabetes (T2D) in East Asians. Nevertheless, the precise mechanism of MOTS-c action has not been fully elucidated. Here, we demonstrate
-
1970-LB: A Sugary Recipe for Adverse Outcomes? Third Trimester HbA1c and Composite Obstetric and Perinatal Adverse Outcomes, a Prospective Study Diabetes (IF 6.2) Pub Date : 2024-07-19 JESSICA HAO-CHEN WU, MARA ULIN, SAMREEN HASSAN, CAMILLE MAI-PHUONG TRAN QUANG, ANUSHA KARRI, DANNIE SIEBEN, FERNANDA ALVARADO, VICTORIA GERALDO, KAMLESH K. JHA, JESSICA C. BISHOP-ROYSE, EDWARD C. LAMPLEY
Objective: to evaluate the association between elevated HbA1c levels close to delivery and the increased risks of composite obstetric and perinatal adverse outcomes. Method: women with singleton pregnancies, at 34 weeks or above admitted for delivery were invited. HbA1c levels were obtained during the admission. The composite obstetrics and perinatal adverse outcomes were collected and analyzed. Results:
-
1092-P: Effectiveness of a Hybrid Care Model for Type 2 Diabetes —A Three-Month Evaluation Diabetes (IF 6.2) Pub Date : 2024-07-19 IHSAN ALMARZOOQI, HALA ZAKARIA, MILENA CACCELLI, CIGDEM OZKAN, JESTONI BANGAYAN, MIRABELLE C. DANDAN, DIANNE JANE DIVINO, SOFIA ALEABOVA, YOUSEF SAID, ALI HASHEMI
Continuous monitoring in diabetes care enhances access, convenience, adherence, and glycemic control. Challenges in digital-only solutions include trust-building and limitations in face-to-face interactions, along with the lack of engagement by care teams outside the clinic setting. A hybrid model where providers incorporate both remote data monitoring and engagement with in-person visits would address
-
1924-LB: Clinical Performance of a Novel CGM System Diabetes (IF 6.2) Pub Date : 2024-07-19 JULIA K. MADER, GUIDO FRECKMANN, THOMAS FORST, GERHARD VOGT, MICHAEL ANGSTMANN, SANDRA MOCERI, DANIEL MILITZ
Introduction and Objective: The use of continuous glucose monitoring (CGM) improves glycemic control in people with diabetes (PwD). The availability of multiple systems with high accuracy allows PwD and their health care professionals to choose the best option for each individual based on respective needs. This study aimed to evaluate the clinical performance of a novel CGM system, the Accu-Chek® SmartGuide
-
349-OR: Reduction of RNA-Editing Enzyme ADAR1 in Human Islets Triggers an Interferon Response and Impairs Beta-Cell Function Diabetes (IF 6.2) Pub Date : 2024-07-19 CHUNHUA DAI, AJAY K. SINGH, REBEKAH BRANTLEY, AMBER BRADLEY, REGINA JENKINS, DIANE C. SAUNDERS, MARCELA BRISSOVA, EREZ LEVANON, AGNES KLOCHENDLER, YUVAL DOR, ALVIN C. POWERS
Introduction & Objective: It is thought that viral infection triggers islet inflammation, an interferon signature, and autoimmunity resulting in type 1 diabetes. Despite extensive research, an inciting virus has not been identified. We hypothesized that impaired RNA editing and accumulation of double-stranded RNA in beta cells triggers an interferon response, causing islet inflammation, autoimmunity
-
336-OR: Females Undergoing Islet Transplantation with CNI-Based Immunosuppression May Be at Higher Risk of Renal Function Decline Diabetes (IF 6.2) Pub Date : 2024-07-19 ALICE L.J. CARR, BRAULIO A. MARFIL-GARZA, ANNA LAM, BLAIRE L. ANDERSON, DOUG O'GORMAN, TATSUYA KIN, DAVID BIGAM, A.M. JAMES SHAPIRO, PETER A. SENIOR
Islet transplantation (ITx) is an established treatment for recurrent, severe hypoglycemia in type 1 diabetes, however, requires lifelong immunosuppression (IS) which can be nephrotoxic. We conducted a risk regression to identify factors associated with progression to Stage 3 CKD (S3CKD) or worse post-ITx. We used data from adults undergoing ITx alone at the University of Alberta Hospital between March
-
350-OR: Parturition Event Regulates Endocrine Genesis during Pancreas Differentiation Diabetes (IF 6.2) Pub Date : 2024-07-19 AGENA SUZUKI, TOMOMI TAGUCHI, SHIORI ITO, HIDEAKI SHIMOTATARA, KAORI KIMURA, NAOYA SHIMIZU, REI FUJISHIMA, MIWA HIMURO, TAKESHI MIYATSUKA
It is essential to decipher developmental features of each endocrine cell, which leads to exploring efficient methods for generating surrogate β cells. We previously developed three reporter mouse lines to quantify the genesis of endocrine progenitor cells, β cells, and α cells. Flow cytometry analysis revealed a significant decrease in the number of newly-generated endocrine progenitors and β cells
-
1020-P: Evolution over Time of the Discrepancy between HbA1c and Glucose Management Indicator—Findings from a Franco-Belgian Cohort of 347 Patients Diabetes (IF 6.2) Pub Date : 2024-07-19 JEAN-PIERRE RIVELINE, GAETAN PREVOST, ANAIS ANDRIEU, MICHAEL JOUBERT, PHILIPPE ORIOT, ALFRED PENFORNIS, JEAN-CHRISTOPHE PHILIPS, JEAN-BAPTISTE JULLA, EMMANUEL COSSON
A discrepancy between laboratory-measured HbA1c and Glucose Management Indicator (GMI), estimated from continuous glucose monitoring, is frequently encountered in clinical practice. However, its evolution over time is not yet known. Methodology: We conducted a multicenter retrospective study (9 centers) that collected pairs of HbA1c and GMI (calculated over 90 days) at T0, T1 year, T2 years of follow-up
-
1563-P: High Fat and Fructose Feeding Severely Impairs Hepatic Glucose Effectiveness but Not Insulin Action Under Euglycemic Conditions Diabetes (IF 6.2) Pub Date : 2024-07-19 DALE S. EDGERTON, GUILLAUME KRAFT, HANNAH L. WATERMAN, BEN FARMER, KALISHA YANKEY, MARTA S. SMITH, JON R. HASTINGS, MELANIE SCOTT, ALAN D. CHERRINGTON
Diets high in fat and fructose (HFHF) disrupt glucose metabolism. This study compared the effects of a HFHF diet on liver insulin action vs glucose effectiveness. Dogs were fed either a chow or HFHF diet for 1 month. At the start of each study, 3-3H-glucose was infused and after a basal sampling period, somatostatin and basal glucagon were given. During the experimental period (4h) either insulin was
-
138-OR: Pioglitazone Amplifies the Decrease in HbA1c and Prevents the Increase in Plasma Ketone Caused by Dapagliflozin in Type 1 Diabetes Mellitus Patients Diabetes (IF 6.2) Pub Date : 2024-07-19 MUHAMMAD ABDUL-GHANI, GOZDE BASKOY, AFIF NAKHLEH, SIHAM ABDELGANI, FAHD AL-MULLA, MOHAMED ABU-FARHA, FAHAD ALAJMI, THAMER ALESSA, RALPH A. DEFRONZO, NAIM SHEHADEH
Introduction and Objectives: SGLT2 inhibitors (SGLT2i) lower the plasma glucose concentration in T1DM patients. However, they cause an increase in plasma ketone concentration and risk of ketoacidosis. The aim of the present study is to examine whether pioglitazone amplifies the decrease in HbA1c and prevents the increase in plasma ketone concentration caused by dapagliflozin in T1DM patients. Methods:
-
1308-P: A Voice-Based AI Algorithm Can Predict Type 2 Diabetes Status—Findings from the Colive Voice Study on U.S. Adult Participants Diabetes (IF 6.2) Pub Date : 2024-07-19 ABIR ELBEJI, MÉGANE PIZZIMENTI, GLORIA A. AGUAYO, AURELIE FISCHER, HANIN AYADI, FRANCK MAUVAIS-JARVIS, JEAN-PIERRE RIVELINE, VLADIMIR DESPOTOVIC, GUY FAGHERAZZI
Introduction: Reducing undiagnosed type 2 diabetes (T2D) cases worldwide is an urgent public health challenge. Most current screening methods are invasive, lab-based, and costly. Meanwhile, there is a growing focus on noninvasive T2D detection through advanced artificial intelligence (AI) and digital technology. This study explores the feasibility of using a voice-based AI algorithm to predict T2D
-
332-OR: Multiomic Profiling of Extended Honeymoon Unveils New Therapeutic Targets Diabetes (IF 6.2) Pub Date : 2024-07-19 CRISTIAN LORETELLI, AHMED GOUDA ABDELRAHMAN ABDELSALAM, MOUFIDA BEN NASR, VERA USUELLI, EMMA ASSI, MONICA ZOCCHI, ADRIANA PETRAZZUOLO, AGNESE PETITTI, GIUSEPPE CANNALIRE, FRANCESCA D'ADDIO, CHIARA MAMELI, PAOLO FIORINA
Introduction & Objective: Approximately 50% of patients with new-onset Type 1 Diabetes (T1D) experience a temporary recovery in pancreatic β-cell function, termed the "honeymoon" (HM) phase, lasting approximately 7-9 months on average, and only rarely extending to years. This phase provides a crucial window for interventions to preserve insulin secretion, yet the factors contributing to its occurrence
-
1004-P: Remote Initiation of Continuous Glucose Monitoring in Older Adults Using Insulin Diabetes (IF 6.2) Pub Date : 2024-07-19 CATHERINE MAHONEY, CHRISTINE SLYNE, MEDHA MUNSHI, COLIN D. CONERY, HALEY BRABANT, NOA KRAKOFF, JANE D. BULGER, RUTH S. WEINSTOCK, ELENA TOSCHI
Background & Objective: Initiation of continuous glucose monitoring (CGM) remotely in adults with diabetes (DM) has been shown beneficial. However, this model has not been evaluated in older adults. The objective of this study was to assess the benefit and challenges encountered by older patients on multiple daily insulin injections (MDI) initiating CGM using a virtual platform. Methods: Older adults
-
1304-P: MODY Calculator Overestimates MODY Probability in Multiethnic Cohort with Youth-Onset Type 2 Diabetes Phenotype Diabetes (IF 6.2) Pub Date : 2024-07-19 RAYMOND J. KREIENKAMP, BEVERLEY SHIELDS, TONI I. POLLIN, MUSTAFA TOSUR, AMY S. SHAH, ANGELA D. LIESE, CATHERINE PIHOKER, SHYLAJA SRINIVASAN, ANDREW T. HATTERSLEY, MIRIAM UDLER, MARIA J. REDONDO
Introduction & Objective: Identifying monogenic diabetes (MODY) remains a challenge for clinicians. Shields and colleagues developed a widely used MODY probability calculator (https://www.diabetesgenes.org/) based on clinical measures to assist in this decision. Because the calculator was developed in a predominantly adult White European population without any pediatric T2D cases, we sought to test
-
1245-P: GDM Patients and Prognostic Factors for Subsequent Type 2 Diabetes Mellitus—An Electronic Cohort Review Diabetes (IF 6.2) Pub Date : 2024-07-19 RYUNG S. KIM, LIHUA LI, CARMEN R. ISASI, ATHENA PHILIS-TSIMIKAS, JEE-YOUNG MOON, JUNXIU LIU, DIANA S. WOLFE, CAROL J. LEVY
Introduction: GDM affects 8-10% of pregnancies in the US and nearly 50% of these women have subsequent diabetes diagnosis. However, research on the prognostic factors of T2D incidence among women with GDM is scarce, due to the limited sample sizes. We aim 1) to construct a large electronic cohort of GDM and 2) to build a prognostic model for T2D incidence among patients with GDM. Methods: We extracted
-
229-OR: Orforglipron Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes Diabetes (IF 6.2) Pub Date : 2024-07-19 JULIO ROSENSTOCK, DEBORAH A. ROBINS, KEVIN L. DUFFIN, JONATHAN M. WILSON, KIEREN J. MATHER, HIYA BANERJEE, YANZHU LIN, SARAH EYDE, CHRISTOF M. KAZDA, MANIGE KONIG
Orforglipron (OFG), an oral, non-peptide GLP-1 receptor agonist, demonstrated significantly greater glycemic control and weight loss at doses ≥12 mg vs placebo (PBO) or dulaglutide (DU) 1.5 mg in a 26-week phase 2 study of adults with type 2 diabetes (T2D) (Table). These exploratory analyses investigated mechanisms by which OFG improved glycemic control in T2D by analyzing exploratory biomarkers. Participants
-
348-OR: Multiancestry Whole Genome Sequencing (WGS) Meta-analysis to Identify Loci Associated with Imaging-Measured Hepatic Steatosis Diabetes (IF 6.2) Pub Date : 2024-07-19 NICHOLETTE ALLRED, CHINMAY RAUT, YANHUA CHEN, ANTONINO OLIVERI, JEFFREY O'CONNELL, KATHLEEN RYAN, JEROME I. ROTTER, STEPHEN S. RICH, AARON HAKIM, PATRICIA PEYSER, LAWRENCE F. BIELAK, CHING-TI LIU, JAMES G. TERRY, MYRIAM FORNAGE, LYNNE E. WAGENKNECHT, ELIZABETH K. SPELIOTES, NHLBI TRANS-OMICS FOR PRECISION MEDICINE (TOPMED)PROGRAM, GOLD CONSORTIUM
Introduction and Objective: Steatotic liver disease, formerly called non-alcoholic fatty liver disease (NAFLD), is the most common cause of chronic liver disease worldwide; yet, few effective methods for prevention/treatment exist making it one of the biggest unmet public health needs of our time. To date, genetic studies have been limited to identifying common variants in predominantly European-ancestry
-
345-OR: Beyond Size Matters—The Impact of Pancreatic Volume and Pancreatic Fat on Type 2 Diabetes Diabetes (IF 6.2) Pub Date : 2024-07-19 HAJIME YAMAZAKI, SHIN-ICHI TAUCHI, MITSURU DOHKE, NAGISA HANAWA, YOSHIHISA KODAMA, AKIO KATANUMA, SHUNICHI FUKUHARA, KATSIARYNA PRYSTUPA, JULIA HUMMEL, ROBERT WAGNER, MARTIN HENI
Introduction & Objective: Individuals with type 2 diabetes (T2D) are thought to have a smaller pancreas; however, whether this is cause or consequence of T2D is unclear. We investigated the association between pancreas volume and T2D risk and whether this association was modified by pancreatic fat. Methods: Using magnetic resonance imaging from the UK Biobank, 25,389 individuals were classified into
-
23-PUB: Reduction of Residual Lipid Risk in Patients with Type 2 Diabetes and Mixed Dyslipidemia Treated with a Fixed-Dose Combination of Atorvastatin/Fenofibrate Diabetes (IF 6.2) Pub Date : 2024-07-19 JOSE G. SANDER-PADILLA, LAURA A. LUGO-SÁNCHEZ, KEVIN F. RIOS-BRITO, KARLA E. RODRIGUEZ-ROCANDIO, MARÍA M. ARGUEDAS, DIANA FLORES-HUANOSTA, ILEANA C. RODRIGUEZ-VAZQUEZ, JORGE GONZALEZ-CANUDAS, YULIA ROMERO
Introduction and Objective: The persistence of a high cardiovascular risk not dependent on LDL-C levels constitutes the residual cardiovascular risk of lipid origin (RLR). Lipid-lowering treatment does not always consider the modification of RLR. The present study aimed to evaluate the changes in RRL profile in patients with T2D and dyslipidemia treated with a fixed-dose combination (FDC) of Atorvastatin/Fenofibrate
-
1301-P: Frequency of Single Autoantibody Positivity (SAB+) Varies by Race/Ethnicity and Area Deprivation Index in Individuals at Risk for Type 1 Diabetes (T1D) Diabetes (IF 6.2) Pub Date : 2024-07-19 ANANTA ADDALA, SUSANNE M. CABRERA, DAVID D. CUTHBERTSON, INGRID LIBMAN, MUSTAFA TOSUR, ALEJANDRO F. SILLER, LINDA A. DIMEGLIO, KEVAN C. HEROLD, MARIA J. REDONDO, HEBA M. ISMAIL
Introduction & Objective: The diversity of individuals living with T1D has increased, driven by Hispanic (H) and non-Hispanic Black (NHB) populations. Yet, whether H and NHB populations have different rates of SAB+ than other groups, which can impact clinical care and research opportunities, has not been well characterized. Area deprivation and race/ethnicity are strongly associated with each other
-
333-OR: Hypoimmune Islet Cells Mediate Insulin Independence after Allogeneic Transplantation in a Fully Immunocompetent Nonhuman Primate without Immunosuppression Diabetes (IF 6.2) Pub Date : 2024-07-19 XIAOMENG HU, KATHY WHITE, CHI YOUNG, ARI G. OLROYD, PAUL KIEVIT, ANDREW CONNOLLY, TOBIAS DEUSE, SONJA SCHREPFER
Treatment of type 1 diabetes mellitus (T1DM) via allogeneic donor transplant has limited success due to morbidities from immunosuppression (IS) and a gradual loss of engrafted pancreatic islet function. We report that allogeneic transplantation of engineered, primary, hypoimmune, pseudo-islets (HIP p-islets) engraft into a fully immunocompetent, diabetic non-human primate (NHP), provide stable endocrine
-
346-OR: Hypothalamic Gliosis Is Associated with CVD Risk Factors in the Framingham Heart Study (FHS) Diabetes (IF 6.2) Pub Date : 2024-07-19 JUSTIN LO, SUSAN J. MELHORN, KELSEY OLERICH, ALYSSA HUANG, SARAH KEE, ALEXA BEISER, SUDHA SESHADRI, CHARLES DECARLI, ELLEN SCHUR
Introduction: Hypothalamic gliosis is linked to obesity and insulin resistance in rodent models and humans. We tested associations between a radiologic measure of hypothalamic gliosis and clinically relevant cardiovascular disease (CVD) risk factors, as well as prevalent coronary heart disease (CHD). Methods: Using brain MRI images from FHS participants (n=867), T2 signal intensities were extracted
-
1073-P: Trends in Guideline-Directed Medication Therapy for Type 2 Diabetes in a Statewide Quality Collaborative between 2018–2023 Diabetes (IF 6.2) Pub Date : 2024-07-19 KARA R. MIZOKAMI-STOUT, LAUREN OSHMAN, HEIDI L. DIEZ, DINA H. GRIAUZDE, JOYCE M. LEE, KATHERINE L. KHOSROVANEH, NEHA BHOMIA, NOA KIM, JACQUELINE RAU, JACOB REISS, RODICA BUSUI
Introduction and Objective: Since 2021, the Michigan Collaborative for Type 2 Diabetes (MCT2D) aims to improve guideline-directed medication therapies (GDMT) for type 2 diabetes (T2D). We examined trends in glucagon-like peptide-1 receptor agonist (GLP-1RA) and sodium-glucose transport protein 2 inhibitor (SGLT2i) prescribing rates comparing primary care (PC) and endocrinology (Endo) practices enrolled
-
240-OR: Longitudinal Assessment of Glycemia and Severe Hypoglycemia among Adults with Type 1 Diabetes—An Online Survey Diabetes (IF 6.2) Pub Date : 2024-07-19 JENNIFER L. SHERR, KAITLIN HAGAN, RACHEL BHAK, MEGAN PETER, HUYEN NGUYEN, CHENKUN WANG, TATHABBAI PAKALAPATI, JORDAN SHERWOOD, TINA GUPTA, JASON L. GAGLIA, EMILEE M. CORNELIUS, KATHERINE S.M. CHAPMAN, WENDY WOLF, JEREMY PETTUS
Introduction & Objective: Longitudinal trends of glycemia and severe hypoglycemic events (SHE) among individuals with T1D are not well described, particularly in those using diabetes technologies (i.e., continuous glucose monitors [CGM], automated insulin delivery [AID]). Methods: An online survey recruited adults with T1D through the T1D Exchange Registry or online communities from February-April
-
1971-LB: Contributions of Fasting and Postprandial Glucose Increments to Overall Hyperglycemia in Pregnant Women with Type 1 Diabetes Diabetes (IF 6.2) Pub Date : 2024-07-19 PING LING, DAIZHI YANG, CHAOFAN WANG, XUEYING ZHENG, SIHUI LUO, XUBIN YANG, HONGRONG DENG, WEN XU, JINHUA YAN, JIANPING WENG
Aims: To evaluate the relative contribution of fasting hyperglycemia (FHG) and postprandial hyperglycemia (PHG) to overall hyperglycemia across time in range (TIR) and glycated hemoglobin (HbA1c) categories in pregnant women with type 1 diabetes mellitus (T1DM). Materials and Methods: This observational study included 112 pregnant women with T1DM from the CARNATION study who wore continuous glucose
-
192-OR: Effect of Video Conferences between Endocrinologists and Family Doctors on Levels of Recommended Medication among Persons with Type 2 Diabetes—Pragmatic RCT Diabetes (IF 6.2) Pub Date : 2024-07-19 THIM PRÆTORIUS, ANNE SOFIE B. LUNDBERG, ESKILD K. FREDSLUND, NIKLAS B. ROSSEN, SØREN GREGERSEN, ANDERS PRIOR, ESBEN SØNDERGAARD, SOREN T. KNUDSEN, ANNELLI SANDBÆK
Introduction and objective: To close treatment gaps in type 2 diabetes (T2D), a 2023 US National Clinical Care Commission calls for testing models of virtual collaboration. We examined the effect of video conferences between endocrinologists and family doctors on levels of recommended medication among persons with T2D seen in family practice. Methods: Two arm, pragmatic RCT with 25 family practices
-
1388-P: Risk of Diabetes among Children and Young Adults after COVID-19 Infection—The DiCAYA Study Diabetes (IF 6.2) Pub Date : 2024-07-19 SARAH CONDERINO, H. LESTER KIRCHNER, LORNA THORPE, JASMIN DIVERS, ANNEMARIE G. HIRSCH, CARA M. NORDBERG, BRIAN S. SCHWARTZ, BO CAI, CAROLINE RUDISILL, JIHAD S. OBEID, ANGELA D. LIESE, BRIAN E. DIXON, DANA DABELEA, ANNA BELLATORRE, HUI SHAO, JIANG BIAN, YI GUO, KRISTI REYNOLDS, MATTHEW T. MEFFORD, MANMOHAN K. KAMBOJ, ENEIDA A. MENDONCA, KATIE ALLEN, SHAWNA BURGETT, EVA LUSTIGOVA, SARAH BOST, MITCH MALTENFORT
Introduction & Objective: The association between COVID-19 infection and incident diabetes remains unclear despite recent research. Using a multistate electronic health record-based surveillance approach, we examined the risk of new diabetes among children (<18) and young adults (18-44) post COVID-19 infection. Methods: Pooled fixed-effects meta-analyses were performed. Patients (n=5,412,604) with
-
1928-LB: Feasibility of Calibration-Free Intradermal Glucose Monitoring Using a Sensor Microarray Diabetes (IF 6.2) Pub Date : 2024-07-19 MARK P. CHRISTIANSEN, NARESH C. BHAVARAJU, REBECCA GOTTLIEB, ALAN CAMPBELL, SIRILAK SATTAYASAMITSATHIT, MARK C. BRISTER, KEITH NOGUEIRA, AMY L. VANDENBERG, RICH YANG, JARED R. TANGNEY
Introduction: Subcutaneous glucose sensors using introducer needles have been well characterized. Robust microsensors are required for a less invasive approach, accessing interstitial glucose in the dermis. Advancements in semiconductor manufacturing have facilitated new sensing technologies using arrays of silicon microsensors on a wearable patch without introducer needles. Several independent electrodes
-
104-OR: State-Dependent Activity in Hindbrain Glucagon-Like Peptide 1—Producing Neurons Regulates Consummatory and Valence Behavior through Functionally Interconnected Hypothalamic and Limbic Circuits Diabetes (IF 6.2) Pub Date : 2024-07-19 MIGUEL DURAN, SONJA VIRKUS, KYLIE A. MCMICHEN, YASLLE ANDRADE CAVALCANTE MORAES, ESHITA YADAV, JAGJOT K. SINGH, ZOE FOKAKIS, SAMANTHA Q. STOCKING, SAMUEL O. POOLE, CHAD S. HUNTER, KIRK M. HABEGGER, JAMES A. HARDAWAY
Introduction: Glucagon-like peptide 1 (GLP-1) therapeutics have experienced a meteoric rise in adoption, but our understanding of the endogenous systems that produce GLP-1 and how they regulate behavior remain incomplete. Preproglucagon neurons in the nucleus of the solitary tract (GcgNTS neurons) are the primary source of GLP-1 in the brain. In this study, we examined the neurophysiological and causal
-
197-OR: Algorithmic Identification May Improve Racial and Ethnic Diversity of Clinical Study Recruitment Diabetes (IF 6.2) Pub Date : 2024-07-19 SARA JANE CROMER, VICTORIA CHEN, MICAH KOSS, MELTON M. FAN, CRISTINA I. FERNÁNDEZ HERNÁNDEZ, WILLIAM G. MARSHALL, EVELYN GREAUX, MIRIAM UDLER
Introduction: Early analyses of Rare and Atypical Diabetes Network (RADIANT) study recruitment suggested that goals to recruit underrepresented groups were not being met. We tested whether a validated electronic health record (EHR) algorithm to identify people with an atypical form of diabetes improved identification of racially and ethnically minoritized individuals who may be candidates for the RADIANT
-
1927-LB: Impact of Continuous Glucose Monitoring Use on Hospitalizations in People with Type 2 Diabetes—Real-World Analysis Diabetes (IF 6.2) Pub Date : 2024-07-19 SATISH K. GARG, IRL B. HIRSCH, ENRICO REPETTO, JANET K. SNELL-BERGEON, BRIAN ULMER, CHRISTOPHER PERKINS, RICHARD M. BERGENSTAL
Introduction & Objective: The increasing prevalence of diabetes in the US continues to drive a steady rise in healthcare resource utilization. The real-world impact of continuous glucose monitoring (CGM) on hospitalizations in a broad type 2 diabetes population is not completely understood. Methods: In this retrospective analysis, we used Optum's de-identified Market Clarity data of >79 million people
-
1559-P: Heterogeneity of Trajectories of Metabolic Parameters after 50% Beta-Cell Mass Loss by Pancreatectomy Diabetes (IF 6.2) Pub Date : 2024-07-19 ROBERTO BIZZOTTO, GIANFRANCO DI GIUSEPPE, LAURA SOLDOVIERI, FRANCESCA CINTI, SIMONA MOFFA, MICHELA BRUNETTI, GEA CICCARELLI, SERGIO ALFIERI, GIUSEPPE QUERO, ANDREA MARI, ANDREA GIACCARI, TERESA MEZZA
Temporal trajectories of metabolic parameters in the onset of dysglycemia are heterogeneous. We aimed to characterize the temporal trajectories of metabolic parameters after β cell mass reduction by pancreatectomy and to study their heterogeneity. Individuals without known diabetes diagnosis (N = 83) underwent mixed-meal/oral glucose tolerance tests (MMTT/OGTT) and/or hyperglycemic/euglycemic clamp
-
1552-P: Mutations with Residual CFTR Function Are Associated to Better Glucose Tolerance and Insulin Secretion in Patients with Cystic Fibrosis Diabetes (IF 6.2) Pub Date : 2024-07-19 ANDREA FOPPIANI, FABIANA CICIRIELLO, FEDERICO ALGHISI, VINCENZINA LUCIDI, FEDERICA SILEO, MARIA CRISTINA LUCANTO, FABIOLA CORTI, CARLA COLOMBO, ALBERTO BATTEZZATI
People with Cystic Fibrosis (pwCF) exhibit a defect of insulin secretion[1], potentially leading to Cystic Fibrosis Related Diabetes. Little information exists about the molecular mechanism that links the defect of insulin secretion to the CF-causing variants of the CFTR gene[2,3]. We sought to describe the relationship between the CFTR function and β-cell function in pwCF. We studied 341 patients
-
1666-P: Effect of Obesity in Family History (FH) on the Prevalence of Type 2 Diabetes Mellitus (T2DM), Hypertension (HT), and Dyslipidemia (DL) Diabetes (IF 6.2) Pub Date : 2024-07-19 IZUMI IKEDA, KAZUYA FUJIHARA, YASUNAGA TAKEDA, CHIKA HORIKAWA, SATORU KODAMA, EFREM D. FERREIRA, YASUMICHI MORI, TAKASHI KADOWAKI, RITSUKO YAMAMOTO-HONDA, YASUJI ARASE, HIROHITO SONE
Heritability and obesity are strongly associated with the prevalence of T2DM, HT, and DL. We compared the effects of an FH of T2DM, HT, and DL combined with obesity on the prevalence of each in the same population. Of 41931 participants who underwent health checkups, the effects of an FH and BMI on the prevalence of those conditions were analyzed cross-sectionally. Prevalences of T2DM, HT, and DL were
-
34-OR: The Effect of Combined Activin A and Myostatin Blockade on Body Composition—A Phase 1 Trial Diabetes (IF 6.2) Pub Date : 2024-07-19 DINKO GONZALEZ TROTTER, STEPHEN DONAHUE, CHRIS WYNNE, SHAZIA ALI, PRODROMOS PARASOGLOU, ANITA BOYAPATI, KUSHA MOHAMMADI, BRET J. MUSSER, PRETTY MEIER, JASON MASTAITIS, EVELYN GASPARINO, JESUS TREJOS, JOHN D. DAVIS, GARY A. HERMAN, ROBERT PORDY
Introduction: Preclinical data suggest myostatin and activin A are important negative regulators of muscle mass. Trevogrumab (a monoclonal antibody [mAb]) binds and blocks myostatin signalling, while garetosmab (a mAb) binds and blocks activin A, AB and AC signalling. Here, the effects of administering trevogrumab and garetosmab, alone or in combination, on body composition in healthy participants
-
1557-P: Increased PAHSA Hydrolysis Driven by Mutant Carboxyl Ester Lipase (CEL) Contributes to Beta-Cell Dysfunction in MODY8 Diabetes (IF 6.2) Pub Date : 2024-07-19 ANNA SANTORO, SEVIM KAHRAMAN, GIORGIO BASILE, KHADIJA EL JELLAS, JIANG HU, RYAN TARPEY, BENTE B. JOHANSSON, ERCUMENT DIRICE, ISMAIL SYED, DIONICIO SIEGEL, ANDERS MOLVEN, BARBARA B. KAHN, ROHIT KULKARNI
Maturity onset diabetes of the young type 8 (MODY8) is caused by genetic mutations in the CEL gene which is expressed primarily in pancreatic acinar cells. MODY8 patients develop pancreatic exocrine and endocrine dysfunction. How the enzymatic function of mutant (MUT) CEL contributes to the development of diabetes in MODY8 is unknown. Palmitic Acid Hydroxy Stearic Acids (PAHSAs) are signaling lipids
-
1555-P: Effects of 80% Pancreas Reduction on Beta-Cell Function and Glucose Metabolism Diabetes (IF 6.2) Pub Date : 2024-07-19 LAURA SOLDOVIERI, GIANFRANCO DI GIUSEPPE, GEA CICCARELLI, MICHELA BRUNETTI, ANDREA MARI, GIUSEPPE QUERO, SERGIO ALFIERI, ANDREA GIACCARI, TERESA MEZZA
Introduction and Objectives: Diabetes typically develops when the endocrine pancreas fails to cope to insulin demand with adequate insulin secretion. Many studies have shown that diabetes appears when the loss of pancreatic β cell mass is approximately between 41% and 65% in humans. Near total pancreatectomy (NTP) is a surgical procedure that removes 80% of pancreatic mass.To investigate the metabolic
-
1229-P: Blood Glycated Albumin or Fructosamine (GA/Fruc) Rather Than Hemoglobin A1c (A1C) Is Useful for Specifying Individuals Having a Macrosomic Baby—Meta-analysis Diabetes (IF 6.2) Pub Date : 2024-07-19 SATORU KODAMA, TAKAHO YAMADA, NORIKO YAGYUDA, KAZUYA FUJIHARA, LAY MON KHIN, MASARU KITAZAWA, MASAHIKO YAMAMOTO, YASUHIRO MATSUBAYASHI, KIMINORI KATO, HIROHITO SONE
Introduction & Objective: Poor glycemic control (GC) increases the risk of various pregnancy complications. Both A1C and GA/Fruc are convenient as they require only one measurement and do not impose fasting. However, GA/Fruc is possibly a better predictor of complications than A1C during pregnancy when GC quickly changes. This meta-analysis compared the predictive ability of pregnancy complications
-
1217-P: Insulin Sensitivity and Insulin Secretion Differentially Affect Birthweight and Postpartum Glucose Diabetes (IF 6.2) Pub Date : 2024-07-19 EMILY A. ROSENBERG, KAITLYN JAMES, DEEPTI PANT, SARAH HSU, ROBIN L. AZEVEDO, CHLOE MICHALOPOULOS, TANAYOTT THAWEETHAI, CAMILLE E. POWE, ARANTXA MEDINA BAEZ
Background: Insulin deficiency and insulin resistance are two fundamental mechanisms that lead to hyperglycemia. Despite variation in the underlying physiology, individuals with hyperglycemia in pregnancy are treated similarly. Methods: Pregnant women with diabetes risk factors completed a 2-hr 75-gram oral glucose tolerance test (OGTT) at 10-15 weeks’ gestation, 24-32 weeks’ gestation, and postpartum
-
155-OR: Genetic Variation and Time to Progression in TN10 (Teplizumab) Diabetes (IF 6.2) Pub Date : 2024-07-19 DOMINIKA A. MICHALEK, SUNA ONENGUT-GUMUSCU, WEI-MIN CHEN, TODD M. BRUSKO, ANDREA STECK, PETER GOTTLIEB, RICHARD A. ORAM, JEFFREY KRISCHER, HEMANG M. PARIKH, MARIA J. REDONDO, KEVAN C. HEROLD, STEPHEN S. RICH
Introduction & Objective: TN10 Anti-CD3 Prevention (TN10) was a randomized phase 2 clinical trial that showed teplizumab delayed progression to type 1 diabetes (T1D) in high-risk participants. Both HLA and non-HLA variants could influence time to progression. Here, genome-wide analysis identified variants and pathways that influence time to progression in TN10 participants. Methods: In TN10, relatives
-
235-OR: Quality of Life and Health Utility 12 Years after Randomization to Bariatric Surgery vs. Medical Therapy in Patients with Type 2 Diabetes and Obesity—The ARMMS-T2D Study Diabetes (IF 6.2) Pub Date : 2024-07-19 DONALD C. SIMONSON, WILLIAM F. GOURASH, DAVID ARTERBURN, BO HU, SANGEETA R. KASHYAP, MARY-ELIZABETH PATTI, PHILIP SCHAUER, DAVID E. CUMMINGS, ANITA COURCOULAS, ALI AMINIAN, JOHN M. JAKICIC, ASHLEY H. VERNON, JOHN P. KIRWAN
Introduction & Objective: T2D and obesity are associated with reduced quality of life (QoL) and health utility (HU), but long-term effects of metabolic/bariatric surgery (MBS) vs. a medical/lifestyle intervention (MLI) on these outcomes are not known. Methods: We studied 228 patients with T2D and obesity who were randomized to MBS (RYGB, gastric band, or sleeve gastrectomy; n = 152) vs. MLI (n = 76)
-
1248-P: Association of Oxidative Stress Markers with Incident Hyperglycemia in Gestational Diabetes Mellitus—Impact of a Diabetes Prevention Program Diabetes (IF 6.2) Pub Date : 2024-07-19 MONICA L. RUIZ, RITA A. GOMEZ-DIAZ, ADRIANA LETICIA VALDEZ GONZALEZ, SELENE ÁNGELES MEJÍA, MARGARITA DIAZ-FLORES, RICARDO C. SALDAÑA ESPINOZA, MARY F. DÍAZ, LUZ ANGELICA RAMIREZ GARCIA, NIELS H. WACHER
Introduction & Objective: Gestational Diabetes (GDM) poses risk for developing type 2 diabetes (T2D). The role of oxidative stress in GDM and its association with incident diabetes remains unclear. This study aimed to assess the link between oxidative stress markers and incident hyperglycemia in women with and without GDM. Methods: Prospective cohort. Pregnant women with GDM (n=201) or without GDM
-
1135-P: Pigment Epithelium–Derived Factor, Diabetic Kidney Disease, and Hypertension—Deciphering the Proteomic Response to Metabolic Bariatric Surgery in Adolescents Diabetes (IF 6.2) Pub Date : 2024-07-19 PHOOM NARONGKIATIKHUN, YE JI CHOI, NHUNG NGUYEN, KELLY NASH, KALIE L. TOMMERDAHL, MATTHIAS KRETZLER, THOMAS INGE, JUSTIN R. RYDER, LAURA PYLE, PETTER BJORNSTAD
Introduction & Objective: This study aims to explore the effects of metabolic bariatric surgery (MBS) on plasma proteins linked to diabetic kidney disease and hypertension in youth with type 2 diabetes (T2D). Methods: We measured 7604 proteins in 326 plasma samples from severely obese youth, both with and without T2D, in the Teen-LABS study, examining pre- and post-MBS changes (6 month, 1, 2-, 3-,
-
121-OR: Safety, Tolerability, and Metabolic Effects of Once-Weekly GL0034 (Utreglutide) in Individuals with Obesity—A Multiple Ascending Dose Study Diabetes (IF 6.2) Pub Date : 2024-07-19 RAJAMANNAR THENNATI, VINOD S. BURADE, MUTHUKUMARAN NATARAJAN, PRADEEP SHAHI, RAVISHANKARA NAGARAJA, SUDEEP K. AGRAWAL, THIERRY DUVAUCHELLE, ADOLFO GARCIA-OCANA, GUY A. RUTTER, RICHARD E. PRATLEY, BERNARD THORENS, TINA VILSBØLL
Introduction & Objective: GL0034 (GL), a once weekly glucagon-like peptide 1 receptor agonist, previously demonstrated significant reductions in body weight (BW) up to Day 22 in a single ascending dose study in individuals with obesity. This phase 1 study assessed the safety, tolerability and metabolic effects of GL after multiple ascending doses. Methods: Individuals with BMI ≥28 kg/m2 (N=24) were
-
Regulation of AMPK and GAPDH by transglutaminase 2 plays a pivotal role in microvascular leakage in diabetic retinas Diabetes (IF 6.2) Pub Date : 2024-07-18 Hye-Yoon Jeon1, Ah-Jun Lee, Chan-Hee Moon, Kwon-Soo Ha
Diabetic retinopathy is the most common microvascular complication caused by chronic hyperglycemia and is a leading cause of blindness; however, the underlying molecular mechanism has not been clearly elucidated. Thus, we investigated whether regulation of AMPactivated protein kinase (AMPK) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by transglutaminase 2 (TGase2) is important for hyperglycemia-induced
-
PTH receptor signalling, osteocytes and bone disease induced by diabetes mellitus Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2024-07-17 Silvia Marino, Teresita Bellido
-
Association of Insulin Resistance With Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes: Systematic Review and Meta-analysis Diabetes Care (IF 14.8) Pub Date : 2024-07-17 Rui Sun, Jianxin Wang, Meng Li, Jingen Li, Yi Pan, Birong Liu, Gregory Y.H. Lip, Lijing Zhang
OBJECTIVE The association of insulin resistance (IR) with cardiovascular disease (CVD) and all-cause mortality in type 1 diabetes (T1D) remains unclear. PURPOSE To investigate whether IR is associated with CVD and all-cause mortality among individuals with T1D. DATA SOURCES PubMed, Embase, and the Cochrane Library databases were searched from inception to 31 October 2023. STUDY SELECTION Observational
-
Association Between Accelerometer-Measured Irregular Sleep Duration and Type 2 Diabetes Risk: A Prospective Cohort Study in the UK Biobank Diabetes Care (IF 14.8) Pub Date : 2024-07-17 Sina Kianersi, Heming Wang, Tamar Sofer, Raymond Noordam, Andrew Phillips, Martin K. Rutter, Susan Redline, Tianyi Huang
OBJECTIVE To evaluate the association between irregular sleep duration and incident diabetes in a U.K. population over 7 years of follow-up. RESEARCH DESIGN AND METHODS Among 84,421 UK Biobank participants (mean age: 62 years) who were free of diabetes at the time of providing accelerometer data in 2013–2015 and prospectively followed until May 2022, sleep duration variability was quantified by the
-
Short-Term Exposure to Wildfire-Specific PM2.5 and Hospitalization for Diabetes Morbidity: A Study in Multiple Countries and Territories Diabetes Care (IF 14.8) Pub Date : 2024-07-16 Yiwen Zhang, Rongbin Xu, Wenzhong Huang, Lidia Morawska, Fay H. Johnston, Michael Abramson, Luke Knibbs, Patricia Matus, Tingting Ye, Wenhua Yu, Simon Hales, Geoffrey Morgan, Zhengyu Yang, Yanming Liu, Ke Ju, Pei Yu, Eric Lavigne, Yao Wu, Bo Wen, Yuxi Zhang, Jane Heyworth, Guy Marks, Paulo H. N. Saldiva, Micheline S. Z. S. Coelho, Yue Leon Guo, Jiangning Song, Yuming Guo, Shanshan Li
OBJECTIVE To evaluate associations of wildfire fine particulate matter (PM2.5) with diabetes across multiple countries and territories. RESEARCH DESIGN AND METHODS We collected data on 3,612,135 diabetes hospitalizations from 1,008 locations in Australia, Brazil, Canada, Chile, New Zealand, Thailand, and Taiwan during 2000–2019. Daily wildfire-specific PM2.5 levels were estimated through chemical transport
-
The challenges of assessing adiposity in a clinical setting Nat. Rev. Endocrinol. (IF 31.0) Pub Date : 2024-07-15 Emma Börgeson, Saeideh Tavajoh, Stephan Lange, Niels Jessen
-
Bidirectional Associations Between Mental Health Disorders and Chronic Diabetic Complications in Individuals With Type 1 or Type 2 Diabetes Diabetes Care (IF 14.8) Pub Date : 2024-07-15 Maya Watanabe, Evan L. Reynolds, Mousumi Banerjee, Morten Charles, Kara Mizokami-Stout, Dana Albright, Lynn Ang, Joyce M. Lee, Rodica Pop-Busui, Eva L. Feldman, Brian C. Callaghan
OBJECTIVE To determine bidirectional associations between the timing of chronic diabetes complications (CDCs) and mental health disorders (MHDs) in individuals with type 1 or type 2 diabetes. RESEARCH DESIGN AND METHODS We used a nationally representative health care claims database to identify matched individuals with type 1 or 2 diabetes or without diabetes using a propensity score quasirandomization
-
Ultra-processed food consumption and risk of diabetes: results from a population-based prospective cohort Diabetol. (IF 8.4) Pub Date : 2024-07-13 Shutong Du, Valerie K. Sullivan, Michael Fang, Lawrence J. Appel, Elizabeth Selvin, Casey M. Rebholz
-
Advances in diabetes technology to improve the lives of people with cystic fibrosis Diabetol. (IF 8.4) Pub Date : 2024-07-12 Kevin J. Scully, Brynn E. Marks, Melissa S. Putman
-
Use of diabetes technology in children Diabetol. (IF 8.4) Pub Date : 2024-07-12 Melissa J. Schoelwer, Mark D. DeBoer, Marc D. Breton
Children with type 1 diabetes and their caregivers face numerous challenges navigating the unpredictability of this complex disease. Although the burden of managing diabetes remains significant, new technology has eased some of the load and allowed children with type 1 diabetes to achieve tighter glycaemic management without fear of excess hypoglycaemia. Continuous glucose monitor use alone improves
-
Rational Pharmacotherapy in Type 2 Diabetes: Danish Data From 2002 to 2020 on Mortality, Diabetes- Related Outcomes, Adverse Events, and Medication Expenses Diabetes Care (IF 14.8) Pub Date : 2024-07-12 Karl Sebastian Johansson, Jimenez-Solem Espen, Tonny Studsgaard Petersen, Mikkel Bring Christensen
OBJECTIVE Developments in pharmacotherapy and management of type 2 diabetes may have shifted the balance of treatment benefits versus harms and costs over the past decades. This study aimed to describe the trends in this balance. RESEARCH DESIGN AND METHODS We followed the Danish population with type 2 diabetes between 2002 and 2020, analyzing their medication use in relation to treatment benefits
-
Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial Diabetol. (IF 8.4) Pub Date : 2024-07-10 Linong Ji, Rikke M. Agesen, Stephen C. Bain, Fangming Fu, Sanaz Gabery, Jianlin Geng, Yiming Li, Yibing Lu, Bifen Luo, Wuyan Pang, Yi Tao
-
Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial Diabetol. (IF 8.4) Pub Date : 2024-07-10 Weiqing Wang, Stephen C. Bain, Fang Bian, Rui Chen, Sanaz Gabery, Shan Huang, Thomas B. Jensen, Bifen Luo, Guoyue Yuan, Guang Ning